128P Precision genomics based targeted 12 gene biomarker and PD-L1 testing in advanced non-small cell lung cancer patients as an alternative to conventional EGFR, ALK, ROS-1 sequential testing in a tertiary care hospital

Abstract

The standard of care in our hospital was conventional EGFR, ALK, ROS1 sequential testing and to treat with chemotherapy if no actionable genetic mutations were detected. With the evolving precision medicine based new targeted treatment for lung cancer patients, we planned a study to develop a new NGS-based assay to identify clinically relevant 12 genes most frequently mutated in non-small cell lung cancer to help patients to benefit from precision genomics based new targeted treatment approaches and to avoid chemotherapy use.